Progyny (NASDAQ:PGNY) Posts Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Progyny (NASDAQ:PGNY) announced its earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.28), Zacks reports. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny updated its Q1 2025 guidance to 0.440-0.470 EPS and its FY 2025 guidance to 1.520-1.620 EPS.

Progyny Trading Down 0.5 %

NASDAQ:PGNY traded down $0.12 during trading hours on Thursday, hitting $22.88. 2,448,924 shares of the company traded hands, compared to its average volume of 1,795,813. The firm has a 50-day moving average of $20.34 and a 200 day moving average of $18.65. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 39.45, a P/E/G ratio of 2.39 and a beta of 1.34. Progyny has a twelve month low of $13.39 and a twelve month high of $38.98.

Insider Activity at Progyny

In other Progyny news, Chairman David J. Schlanger acquired 150,000 shares of Progyny stock in a transaction dated Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter Anevski acquired 209,500 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on PGNY. Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Canaccord Genuity Group lowered their price target on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Barclays reduced their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 price objective (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $25.83.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.